Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CIN-103
- Development stage
- Discontinued
- Lead developer
- CinPhloro Pharma
- Modality
- Small Molecules, Device-based Delivery → Drug Delivery Systems
- Administration
- Oral
01
Overview
CIN-103 is a small-molecule, modified pulsatile-release formulation of phloroglucinol, a phenol-derivative with antispasmodic properties. It is being developed for irritable bowel syndrome with predominant diarrhea (IBS-D). This novel formulation utilizes a proprietary pulsatile delivery system combining immediate-release and delayed-release processes designed to sustain exposure, maintain efficacy, and reduce dosing frequency compared to traditional phloroglucinol formulations. It is believed to target multiple IBS-D action points, including motility, secretion, pain, spasms, and inflammation. As a non-opioid based small molecule, it functions as an antispasmodic that specifically targets and relaxes smooth muscles in the gut, aiming to relieve abdominal pain and spasms.
Beyond the preview
Go deeper on CIN-103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CIN-103.